+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 34 Actively Recruiting clinical trials

R

Actively Recruiting

Researchers are evaluating the efficacy and safety of HBS-301 in adults aged 18 years and older who have idiopathic hypersomnia IH, a condition characterized by excessive daytime sleepiness EDS. This Phase 3 clinical trial is randomized, double-blind, and placebo-controlled, aiming to better understand how HBS-301 affects the severity of sleepiness and other IH symptoms compared to placebo. Participants will be randomly assigned to receive either HBS-301 tablets or matching placebo tablets once daily in the morning upon waking during an 8-week double-blind treatment period. After this, participants may choose to join an optional 1-year open-label extension where all receive HBS-301. The study begins with a screening and baseline period lasting up to 28 days, followed by 30 days of safety follow-up after treatment ends. During the trial, participants will have regular assessments including questionnaires measuring sleepiness severity using the Epworth Sleepiness Scale and other scales evaluating IH symptoms, sleep inertia, fatigue, cognition, quality of life, and work productivity. Safety monitoring includes tracking any adverse events throughout the 16 months of the study. Participants will be involved in scheduled visits for evaluations and treatment adherence, with the primary focus on changes in daytime sleepiness severity over the 8-week treatment period.

Age: 18Years +All GendersPhase 3
42 locations
P

Actively Recruiting

Researchers are conducting a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the effectiveness and safety of HBS-301 in adults aged 18 years and older with narcolepsy. The study focuses on treating excessive daytime sleepiness EDS, cataplexy, sleepinesswakefulness, and fatigue in this population. Participants will be randomly assigned to receive either HBS-301 tablets or matching placebo tablets once daily in the morning upon waking during an 8-week double-blind treatment period. After this, participants may opt into a one-year open-label extension where all receive HBS-301. The study begins with a screening and baseline period lasting up to 28 days, followed by the treatment phases, and concludes with a 30-day safety follow-up. During the study, participants will undergo various assessments including the Epworth Sleepiness Scale to measure changes in daytime sleepiness, evaluations of cataplexy frequency, fatigue levels, sleepinesswakefulness tests, and quality of life questionnaires. Safety will be monitored throughout the entire study duration of approximately 16 months. Participants will have scheduled visits for assessments during each phase to track treatment effects and safety.

Age: 18Years +All GendersPhase 3
53 locations
S

Actively Recruiting

This research aims to describe the characteristics of people with asthma, covering a wide range of disease severities. It studies sociodemographic and clinical features, treatment patterns, disease burden, biomarkers, and health-related quality of life. The study includes both a cross-sectional part and a prospective follow-up to observe changes in asthma over time. Participants are grouped based on their asthma treatments and disease control, including those receiving various doses of inhaled corticosteroids or biologic therapies as part of their usual care. The study has two main parts Part 1 assesses characteristics at baseline, while Part 2 follows participants for two years to evaluate changes in symptoms, lung function, treatment use, and biomarkers. During the study, participants will provide information through questionnaires and clinical assessments, including lung tests and blood samples. Researchers will collect both participant- and physician-reported outcomes to analyze asthma severity, control, quality of life, and healthcare use. The study extends up to two years, with evaluations at baseline and at weeks 52 and 104 to understand disease progression and treatment patterns.

Age: 6Years +All Genders
71 locations
P

Actively Recruiting

Researchers are evaluating disitamab vedotin alone or combined with pembrolizumab to treat urothelial cancer that expresses HER2. This study focuses on participants with locally advanced or metastatic urothelial cancer that cannot be removed by surgery. It aims to assess how well the drug works and to monitor the side effects experienced by participants. Participants receive disitamab vedotin intravenously every 2 weeks, either alone or with pembrolizumab given by intravenous infusion on Day 1 of each 6-week cycle. The study includes multiple cohorts receiving different combinations or monotherapy treatments. The treatment period and monitoring last approximately 2 years, with ongoing assessments of drug effects and safety. During the study, participants undergo regular evaluations including imaging scans to measure tumor response, laboratory tests, electrocardiograms to monitor heart function, and assessments of side effects. Researchers measure treatment response using established cancer evaluation criteria and track survival and disease control over about 3 years. Participants are closely monitored for adverse effects and blood levels of the drugs to understand how the treatments behave in the body.

Age: 18Years +All GendersPhase 2
221 locations
E

Actively Recruiting

Researchers are evaluating GB-0895 as an additional therapy for adolescents and adults with severe asthma that remains uncontrolled despite treatment with inhaled corticosteroids and other standard asthma controllers. This global, multicenter, randomized, double-blind, placebo-controlled Phase 3 study aims to assess the efficacy and safety of GB-0895 in improving health outcomes for this population, with an optional open-label extension phase. Participants will receive subcutaneous injections of either GB-0895 or a placebo every six months over a 52-week treatment period. The study includes a screening and run-in phase lasting up to five weeks before treatment starts. After the treatment phase, participants will enter a follow-up period lasting from week 52 to week 90 or may opt to join an open-label extension lasting until week 142. During the study, participants will be regularly assessed for asthma exacerbations, lung function changes, quality of life, symptom control, and safety measures including lab tests, vital signs, and ECGs. Researchers will monitor the annualized asthma exacerbation rate as the primary outcome and evaluate additional respiratory and quality of life assessments. The total participation time may extend up to nearly three years for those in the optional open-label extension.

Age: 12Years - 80YearsAll GendersPhase 3
134 locations
E

Actively Recruiting

Researchers are evaluating the safety and effects of a study medicine called PF-07275315 for treating adults with moderate-to-severe asthma that is not well controlled. Asthma is a condition that makes breathing difficult and affects quality of life. This phase 2 clinical trial includes participants aged 18 to 75 who have had moderate-to-severe asthma for at least 12 months and have been on maintenance asthma treatment for the past 6 months. Participants will receive either PF-07275315 or a placebo, both given as multiple subcutaneous injections in the clinic over 12 weeks. The study compares experiences between those receiving the study medicine and those receiving placebo to assess safety and effects. The trial is randomized, double-blind, and placebo-controlled with parallel groups. During the study, participants will be involved for up to approximately 9.5 months depending on local regulations. They will have regular visits for injections and assessments including lung function tests like FEV1, questionnaires about asthma control and quality of life, and safety monitoring through lab tests, vital signs, and electrocardiograms. Researchers will track changes from baseline in lung function and adverse events up to 24 weeks after treatment begins.

Age: 18Years - 75YearsAll GendersPhase 2
137 locations
E

Actively Recruiting

Researchers are studying adults newly diagnosed with breast, colorectal, melanoma, non-Hodgkin lymphoma, or non-small cell lung cancers who are starting systemic cancer treatments such as chemotherapy or immune checkpoint inhibitors. The purpose is to understand how cannabis and cannabinoid use relates to cancer-related symptoms over one year. This observational study enrolls 2000 participants to explore these associations in community oncology settings. Participants do not receive any experimental treatments but complete surveys and have their medical records reviewed. Assessments occur monthly for up to 12 months, capturing cannabis use, perceived benefits and harms, and adverse effects alongside symptom tracking. There is an optional sub-study for some participants receiving immune checkpoint inhibitors at specific cancer centers. During the study, participants complete monthly surveys either online at home, in clinic, or other locations, and their medical records are reviewed for treatment and symptom information. Researchers measure cancer-related symptoms and cannabis use patterns over time. The study monitors participants for up to one year to evaluate symptom changes and cannabis-related effects, with no intervention administered by the study team.

Age: 18Years +All Genders
491 locations
N

Actively Recruiting

Researchers are collecting biological samples and medical data from patients who experience serious side effects after receiving immunotherapy treatments for cancer. This observational study aims to build a national collection of these samples and data to help future research better predict, prevent, and manage these immune-related adverse events, rare infections, or rapid tumor growth. Participants provide tissue, blood, and optionally stool samples if they experience colitis, shortly after confirmation of a severe immune-related side effect and again one month later. Their medical records will be reviewed for up to one year to gather detailed clinical information. This study does not involve administering treatments but focuses on collecting data and samples from those already treated with immuno-oncology therapies. During the study, participants undergo sample collections at registration and one month later. Researchers will review medical records over a year to monitor health outcomes and side effects. The main measurement is establishing the biorepository of samples and data for future studies. Participation duration can last up to one year with periodic assessments based on medical record review and sample collection.

All AgesAll Genders
630 locations
E

Actively Recruiting

Researchers are evaluating how to best recommend chemotherapy for patients with colon cancer based on the presence or absence of circulating tumor DNA ctDNA after surgery. This Phase IIIII trial aims to determine if ctDNA can be used to better identify patients who need adjuvant chemotherapy and to assess optimal chemotherapy regimens for those with detectable ctDNA, as current biomarkers have not been prospectively validated. Participants are assigned to different groups based on their ctDNA status after surgery. Those without detectable ctDNA may undergo serial ctDNA monitoring without treatment or receive shorter chemotherapy regimens. Patients with detectable ctDNA receive more intensive chemotherapy options, including combinations of oxaliplatin, leucovorin, 5-fluorouracil, irinotecan, or capecitabine, administered intravenously or orally over cycles lasting several weeks. The study includes randomization and uses the Signatera test for central ctDNA detection. During the study, participants will undergo regular blood tests for ctDNA status, imaging scans, and clinical assessments. Researchers will track ctDNA positivity over up to 3 years and disease-free survival over up to 5 years. Other measures include overall survival, recurrence rates, and chemotherapy compliance. The total study duration may extend several years with ongoing monitoring to evaluate safety and treatment outcomes.

Age: 18Years +All GendersPhase 2Phase 3
1085 locations
P

Actively Recruiting

Researchers are assessing three different methods to prevent peripheral neuropathy caused by taxane chemotherapy drugs like paclitaxel or docetaxel. This phase III trial compares cryocompression, continuous compression, and low cyclic compression therapies using the Paxman Limb Cryocompression System, which applies cooling andor pressure to the arms and legs. The study aims to see if any of these approaches can reduce the nerve damage that leads to numbness, tingling, or pain during chemotherapy. Participants are randomly assigned to one of three groups cryocompression therapy cooling plus moderate and low pressure, continuous compression therapy steady moderate pressure, or low cyclic compression therapy low pressure that cycles on and off. Each therapy is applied for 30 minutes before, during, and after each taxane chemotherapy infusion. Blood, serum, and plasma samples may be collected during screening and throughout the study. During the study, participants will complete questionnaires and undergo evaluations of nerve function and physical tests at multiple time points up to 52 weeks. Researchers will monitor side effects related to the devices, participant satisfaction, and chemotherapy dosing impacts. The main outcome measured is the occurrence of clinically meaningful chemotherapy-induced peripheral neuropathy at 12 weeks after starting treatment, with additional assessments over time to understand the therapies effects and tolerability.

Age: 18Years +All GendersPhase 3
36 locations

1-10 of 34

1